SCHEMBL4297485

SCHEMBL4297485

COc1ccc(N(C)c2cc(Cl)nc(N)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.52
POLB P06746 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
DHFR P00374 1/20 0.49
HSP90AA1 P07900 4/20 0.49
HSP90AB1 P08238 4/20 0.49
TUBB3 Q13509 4/20 0.47
TUBB4A P04350 3/20 0.47
TUBB P07437 3/20 0.47
TUBA3C P0DPH7 3/20 0.47
TUBA1B P68363 3/20 0.47
TUBA4A P68366 3/20 0.47
TUBB4B P68371 3/20 0.47
TUBB2A Q13885 3/20 0.47
TUBB8 Q3ZCM7 3/20 0.47
TUBA3E Q6PEY2 3/20 0.47
TUBA1A Q71U36 3/20 0.47
TUBA1C Q9BQE3 3/20 0.47
TUBB6 Q9BUF5 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1317516 0.81 SMN1; SMN2 (0.61) SMN1; SMN2DHFRHSP90AA1HSP90AB1KMT2A
SCHEMBL28736302 0.79 SMN1; SMN2 (0.71) SMN1; SMN2POLBGAAMAPTDHFR
SCHEMBL29610081 0.79 SMN1; SMN2 (0.71) SMN1; SMN2POLBGAAMAPTDHFR
SCHEMBL6265152 0.77 KMT2A (0.55) SMN1; SMN2POLBGAAMAPTHSP90AA1
SCHEMBL12488038 0.76 TUBB4A (0.46) SMN1; SMN2DHFRTUBB3TUBB4ATUBB
SCHEMBL4300255 0.75 MEN1 (0.53) SMN1; SMN2MAPTTUBB3TUBB4ATUBB
SCHEMBL2724359 0.72 SMN1; SMN2 (0.48) SMN1; SMN2MAPTDHFRHSP90AA1HSP90AB1
SCHEMBL1644753 0.72 DYRK1A (0.71) SMN1; SMN2POLBGAAMAPTHSP90AA1
SCHEMBL6345046 0.72 EGFR (0.41) SMN1; SMN2POLBGAAMAPTDHFR
SCHEMBL1320790 0.71 KMT2A (0.63) SMN1; SMN2MAPTHSP90AA1HSP90AB1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090280133-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-12 US claimed
US-20090280133-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-12 US disclosed
US-20090280133-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-12 US disclosed
US-20090280133-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-12 US disclosed
WO-2008061112-A9 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS INC (US) 2008-09-18 WO disclosed
WO-2008061112-A2 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INC. (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090280133-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MKI67, CCNI, CCNA1 SMN1; SMN2 1498/4885POLB 1329/4885GAA 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.